Foghorn Therapeutics (FHTX) risk factors, FY2024 10-K

Risks Related to Our Financial Position and Need for Additional Capital

1. 01We have a limited operating history and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability
2. 02We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability
3. 03We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts
4. 04We have never generated revenue from product sales and may never be profitable
5. 05Unfavorable global macroeconomic conditions, geopolitical trends, and armed conflict could adversely affect our business, financial condition or results of operations
6. 06U.S. federal income tax reform could adversely affect our business and financial condition
7. 07Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited

Risks Related to Discovery and Development

1. 08Our clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would delay or prevent regulatory approval of the product candidates, limit the commercial potential, or result in significant negative consequences following any potential marketing approval
2. 09Any of these events could prevent us from achieving or maintaining market acceptance of any product candidates we may identify and develop and could have a material adverse effect on our business, financial condition, results of operations, and prospects
3. 10We may not be able to file INDs or IND amendments to commence clinical trials of our product candidates on the timelines we or our partners expect, and even if we are able to, the FDA may not permit us to proceed
4. 11There is substantial competition in our field, which may result in others developing or commercializing products before we do
5. 12Product development is a lengthy and expensive process with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates
6. 13We are not be able to exert unilateral control over the development of product candidates when part of a collaboration
7. 14If we experience delays or difficulties in the enrollment and dosing of patients in our clinical trials, our receipt of necessary regulatory approvals for our product candidates could be delayed or prevented
8. 15Any favorable preclinical results may not be predictive of results that may be observed in clinical trials
9. 16Our approach to the discovery of product candidates is unproven, and we may not be successful in our efforts to use and expand our platform to build a pipeline of product candidates with commercial value
10. 17We rely on third parties to perform pre-clinical experiments, to manufacture our preclinical and clinical product supplies, to produce and process clinical quantities of our product candidates and to assist with clinical trials

Risks Related to Employee Matters, Managing Growth and Information Technology

1. 18We are highly dependent on our key personnel. If we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
2. 19We may need to grow the size of our organization, and we may experience difficulties in managing this growth and other issues relating to our employees
3. 20Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of the development programs of our product candidates
4. 21Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses

Risks Related to Our Intellectual Property

1. 22pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights cannot be predicted with any certainty
2. 23If we are unable to protect the confidentiality of our trade secrets, our business and competitive position may be harmed
3. 24Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
4. 25The intellectual property landscape around our technology, including our Gene Traffic Control platform, is highly dynamic, and third parties may obtain intellectual property rights that could affect our ability to use our platform or otherwise develop and commercialize product candidates
5. 26Our commercial success depends in part upon our ability and the ability of our collaborators to develop, manufacture and sell our product candidates and use our proprietary technologies without infringing the propriety rights and intellectual property of third parties
6. 27We may be subject to damages resulting from claims that we or our employees have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors
7. 28We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time-consuming and unsuccessful
8. 29Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities
9. 30We may not be able to effectively enforce our intellectual property rights throughout the world
10. 31We may be subject to claims challenging the inventorship or ownership of any intellectual property, including any patents we may own or in-license in the future
11. 32If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed
12. 33Intellectual property rights do not necessarily address all potential threats
13. 34Changes to the patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our product candidates

Risks Related to Our Reliance on Third Parties

1. 35In addition, certain of our CDMOs and CROs located in China may experience adverse legal and regulatory restrictions, which could adversely affect their ability to provide services to us and, thereby, harm our business
2. 36We do not currently own any facility that may be used as our clinical-scale manufacturing and processing facility and instead must currently rely on outside vendors to manufacture our product candidates in clinical quantities
3. 37If our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for damages
4. 38Our business is exposed to risks from operating with third parties, particularly those outside the United States

Risks Related to Regulatory and Other Legal Compliance Matters

1. 39Our clinical trials may fail to demonstrate adequately the safety and efficacy of any of our product candidates, which would delay or prevent further clinical development of those candidates
2. 40To obtain the requisite regulatory approvals to market and sell any of our product candidates, including FHD-909, and any other future product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our products are safe and effective in humans
3. 41We may in the future seek orphan drug status for our product candidates, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug status, including market exclusivity, which may cause our future revenue, if any, to be reduced
4. 42orphan exclusivity that the FDA previously has recognized for our products. Furthermore, the FDA can waive orphan drug exclusivity if we are unable to manufacture sufficient supply of our product
5. 43A Breakthrough Therapy designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval
6. 44Healthcare legislative reform measures may have a material adverse effect on our business and results of operations
7. 45The successful commercialization of our product candidates will depend in part on the extent to which third-party payors establish coverage, adequate reimbursement levels and pricing policies
8. 46We are subject to U.S. and international restrictive regulations governing the use, processing and cross-border transfer of data and personal information
9. 47The market price of our common stock may be volatile, which could result in substantial losses for our stockholders
10. 48If securities analysts cease to publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
11. 49A significant portion of our total outstanding shares is eligible to be sold into the market, which could cause the market price of our common stock to drop significantly, even if our business is doing well
12. 50Insiders have substantial influence over us, which could limit your ability to affect the outcome of key transactions, including a change of control
13. 51We are an “emerging growth company,” and the reduced disclosure requirements applicable to emerging growth companies may make our common stock less attractive to investors
14. 52These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock
15. 53outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner